SCORE 2—Sponsored by NIH, National Eye Institute& U.S. Department of Health & Human ServicesCompleted Study | Duration: 12 Months
Study of Comparative Treatments in Retinal Vein Occlusion 2 (SCORE2)
SCORE2 was a multi center, prospective, randomized Phase III clinical trial for the treatment of Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). It was a non-inferiority trial that compared the treatment outcome of intravitreal Bevacizumab 1.25mg (Avastin) vs. intravitreal aflibercept 2.0mg (Eylea). Both drugs were injected once every four weeks in the study eye over the same period of time. Participants were followed for 12 months, and primary outcome was measured at the 6-months mark.